scholarly journals Endothelin A Receptor Blockade Improves Endothelium-Dependent Relaxation in Obese Woman

2018 ◽  
pp. S167-S174
Author(s):  
K. GRADIN ◽  
B. PERSSON
Keyword(s):  
Gastric Bypass ◽  
Obese Woman ◽  
Gastric Bypass Surgery ◽  
Response Curves ◽  
No Donor ◽  
Hypertensive Patients ◽  
Functional Studies ◽  
Eta Receptor ◽  
Eta Receptor Antagonist ◽  
Synthase Inhibitor

Hypertension in obesity is associated with increased insulin resistance, vascular mass and body mass index (BMI). The purpose of the study was to visualize endothelin-1 (ET-1) mediated constriction in arteries isolated from subcutaneous adipose tissue from obese hypertensive women previously operated by gastric bypass. Functional studies were conducted in a microvascular myograph. Expressed as percentage of contraction elicited by 124 mM KCl concentration-response curves for ET-1 were shifted leftward in arteries from obese hypertensive patients compared to healthy normotensive subjects. The vasodilator response to the ET-1 antagonist BQ123 (1 µM) was significantly higher in arteries from obese hypertensive patients (p<0.001). BQ123 induced relaxation was inhibited by NO synthase inhibitor L-NAME (0.1 nM). Preincubation with BQ123 enhanced the relaxation induced by acetylcholine (ACh; 0.1 nM – 0.1 mM) (p<0.001), but not that induced by NO donor sodium nitroprusside (SNP; 0.1 nM – 0.1 mM), in arteries from obese hypertensive patients. The present study show that hypertension yet prevail after gastric bypass surgery and the ETA receptor antagonist BQ123 may be a useful tool in reducing blood pressure in obese hypertensive patients.

scholarly journals Role of endothelial carbon monoxide in attenuated vasoreactivity following chronic hypoxia

1998 ◽  
Vol 275 (4) ◽  
pp. R1025-R1030 ◽  
Author(s):  
Timothy K. Caudill ◽  
Thomas C. Resta ◽  
Nancy L. Kanagy ◽  
Benjimen R. Walker
Keyword(s):  
Chronic Hypoxia ◽  
Soluble Guanylyl Cyclase ◽  
Hypoxic Exposure ◽  
Zinc Protoporphyrin ◽  
Response Curves ◽  
No Donor ◽  
Enhanced Production ◽  
Synthase Inhibitor

Chronic hypoxic exposure has been previously demonstrated to attenuate systemic vasoconstrictor activity to a variety of agents. This attenuated responsiveness is observed not only in conscious animals but in isolated vascular preparations as well. Because hypoxia has been documented to increase heme oxygenase (HO) levels and the subsequent production of the vasodilator CO in vitro, we hypothesized that the blunted reactivity observed with chronic hypoxia (CH) may be in part due to increased HO activity. In thoracic aortic rings from CH rats, cumulative dose-response curves to phenylephrine (PE) in the presence of the nitric oxide (NO) synthase inhibitor N ω-nitro-l-arginine (l-NNA) and the HO inhibitor zinc protoporphyrin 9 (ZnPPIX) elicited increased contractility compared with CH rings treated with onlyl-NNA. Similar results were observed in rings incubated overnight with the HO-inducing agent sodium m-arsenite. In contrast, contractile responses in rings from control rats were unaffected by the HO inhibitor. Furthermore, endothelium-denuded rings from either control or CH rats did not exhibit an increase in reactivity to PE following ZnPPIX incubation. ZnPPIX had no effect on relaxant responses to the NO donor S-nitroso- N-penicillamine, suggesting that its actions were specific to HO inhibition. Finally, aortic rings exhibited dose-dependent relaxant responses to exogenous CO that were endothelium independent and blocked by an inhibitor of soluble guanylyl cyclase. The other products of HO enzyme activity, iron and biliverdin, were without effect on vasoreactivity. Thus we conclude that the attenuated vasoreactivity to PE following CH is likely to involve the induction of endothelial HO and the subsequent enhanced production of CO.

Characterization of endothelin receptors mediating contraction of rabbit saphenous vein

1994 ◽  
Vol 266 (3) ◽  
pp. H959-H966 ◽  
Author(s):  
G. A. Gray ◽  
B. M. Loffler ◽  
M. Clozel
Keyword(s):  
Saphenous Vein ◽  
Plasma Membranes ◽  
Receptor Subtypes ◽  
Functional Studies ◽  
Eta Receptor ◽  
Etb Receptor ◽  
Minor Part ◽  
Eta Receptor Antagonist ◽  
A Site

The goal of this study was to characterize endothelin (ET) receptors mediating contraction of the rabbit saphenous vein. For this purpose, binding and functional studies were performed. Two receptor subtypes mediated contraction in response to ET-1. The first, responsible for 80-90% of maximal contraction, was stimulated with equal potency by ET-1, ET-3, and sarafotoxin S6c. The second, responsible for the remaining contraction, was stimulated more potently by ET-1 than by ET-3 and not by sarafotoxin S6c. The specific ETA receptor antagonist BQ-123 and the inhibitor of protein kinase C (PKC) Ro 31-8220 inhibited ET-1 contraction via the second but not the first receptor. In plasma membranes 125I-labeled ET-1 bound predominantly to a site with characteristics of ETA receptor, whereas 125I-ET-3 bound to two sites with characteristics of ETB receptor, one of high and one of low affinity. Comparison of binding affinity constants and 50% effective concentrations shows that the high-affinity ETB receptor corresponds to the receptor mediating the major part of contraction independently of PKC activation and ETA to the receptor mediating the minor part of contraction via a PKC-dependent mechanism.

Endothelin stimulates an endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, in experimental heart failure

2002 ◽  
Vol 103 (s2002) ◽  
pp. 241S-244S ◽  
Author(s):  
Masato OHNISHI ◽  
Atsuyuki WADA ◽  
Takayoshi TSUTAMOTO ◽  
Masanori FUJII ◽  
Takehiro MATSUMOTO ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Vascular Resistance ◽  
Vascular Tone ◽  
Asymmetric Dimethylarginine ◽  
No Production ◽  
Plasma Adma ◽  
Eta Receptor ◽  
Eta Receptor Antagonist ◽  
Synthase Inhibitor ◽  
Regulation Of Vascular Tone

Congestive heart failure (CHF) is characterized by increased peripheral vascular resistance. Endothelin-1 (ET-1), a potent endothelium-derived vasoconstrictor, is present at increased concentrations in the plasma and contributes to the regulation of vascular tone in CHF. An endothelium-derived relaxing factor, nitric oxide (NO), also regulates vascular tone, but endothelium-dependent NO-mediated vasodilation is blunted in CHF. An endogenous NO synthase inhibitor, asymmetric dimethylarginine (ADMA), which inhibits NO production and endothelium-dependent relaxation, is present at increased levels in the plasma and plays a role in impaired endothelial function in CHF. However, at present, the relationship between ET-1 and impaired vascular relaxation in CHF is not well known. We hypothesized that ET-1 inhibits NO-mediated vasodilation via increased ADMA production in CHF, and that an endothelin receptor antagonist can prevent this increase in plasma ADMA levels. In the present study, we first examined whether circulating ADMA levels were increased in a dog model of CHF induced by 3 weeks of rapid ventricular pacing (n = 5; 270beats/min) compared with normal dogs (n = 5). After 3 weeks of pacing, cardiac output had decreased significantly (1.56±0.16 compared with 2.93±0.25litres/min; P<0.01) and systemic vascular resistance had increased (4653±374 compared with 3227±396dyn·s·cm-5; P<0.01) in dogs with CHF compared with normal dogs. Plasma levels of both ET-1 (4.95±0.83 compared with 2.12±0.39pg/ml; P<0.05) and ADMA (3.27±0.49 compared with 1.91±0.25nmol/ml; P<0.05) were significantly increased in CHF dogs. A significant positive correlation was observed between plasma ET-1 and ADMA levels (r = 0.72, P<0.05). Secondly, we chronically administered an ETA receptor antagonist, TA-0201 (0.3mg/kg; n = 5), to paced CHF dogs. Drug administration started on day 8 of pacing and continued throughout the experiment. TA-0201 significantly increased cardiac output (2.58±0.24litres/min; P<0.01) and suppressed the increases in plasma ADMA levels and systemic vascular resistance (2.36±0.30nmol/ml and 2423±188dyn·s·cm-5 respectively; P<0.05 for each) compared with CHF dogs without TA-0201 treatment. In conclusion, ET-1 contributes to the regulation of vascular tone due, in part, to increased levels of an endogenous NO synthase inhibitor in CHF, and an ETA receptor antagonist can prevent the inhibition of NO production and the increased peripheral vascular resistance observed in CHF.

scholarly journals Pharmacological Modulation of Mucosa-Related Impairment of β-Adrenoceptor-Mediated Relaxation in Human Detrusor

2015 ◽  
Vol 95 (3) ◽  
pp. 300-308 ◽  
Author(s):  
Stefan Propping ◽  
Melanie Roedel ◽  
Manfred P. Wirth ◽  
Ursula Ravens
Keyword(s):  
Receptor Antagonist ◽  
Force Measurement ◽  
P2x Receptor ◽  
Nitric Oxide Synthase Inhibitor ◽  
Eta Receptor ◽  
Etb Receptor ◽  
Set Up ◽  
Eta Receptor Antagonist ◽  
Synthase Inhibitor ◽  
Human Detrusor

Objectives: The mucosa of human detrusor strips impairs catecholamine-induced relaxation. In order to elucidate which signal transduction pathways are involved in this cross talk between the mucosa and detrusor, we have studied the effects of several pharmacological agonists and antagonists on noradrenaline-mediated relaxation in intact and mucosa-denuded detrusor strips. Patients and Methods: Strips of detrusor tissue were obtained from patients who had undergone cystectomy for bladder cancer and were set up for force measurement. KCl- or carbachol-precontracted strips were relaxed with increasing concentrations of noradrenaline in the absence and in the presence of nitric oxide synthase inhibitor, L-NAME; P2X-receptor antagonist, PPADS; ETA-receptor antagonist, BQ-123; ETB-receptor antagonist, BQ-788; cyclooxygenase inhibitor, diclofenac; AT1-receptor antagonist, candesartan; and NK1-receptor antagonist, L-703,606. Results: In intact strips, KCl-stimulated force was enhanced by all blockers; carbachol-stimulated force increased with L-703,606. In denuded strips, only L-NAME augmented the KCl-stimulated contraction. Noradrenaline relaxed the precontracted detrusor strips to a significantly larger extent and at lower concentrations in denuded than in intact strips. L-NAME, PPADS and BQ-123/BQ-788 had little effect on noradrenaline-induced relaxation, whereas diclofenac, candesartan and L-703,606 sensitized intact carbachol-stimulated detrusor strips to noradrenaline-induced relaxation. Conclusion: Inhibition of the noradrenaline-induced relaxation of precontracted human detrusor strips by the mucosa is attenuated by diclofenac, candesartan and L-703,606 suggesting the involvement of prostanoids, angiotensin and neurokinin pathways. Further experiments are required to unravel the exact mechanisms.

Abstract #607: Gastric Bypass Surgery is Associated with A Reduction in Vasoconstrictive Mediators

2017 ◽  
Vol 23 ◽  
pp. 124-125
Author(s):  
Paresh Dandona ◽  
Husam Ghanim ◽  
Scott Monte ◽  
Joseph Caruana ◽  
Mayuri Mudgal ◽  
...  
Keyword(s):  
Gastric Bypass ◽  
Bypass Surgery ◽  
Gastric Bypass Surgery

Ridogrel Inhibits Systemic and Renal Formation of Thromboxane A2 and Antagonizes Platelet Thromboxane A2/Prostaglandin Endoperoxide Receptors upon Chronic Administration to Man

1992 ◽  
Vol 68 (02) ◽  
pp. 214-220 ◽  
Author(s):  
C Weber ◽  
J R Beetens ◽  
F Tegtmeier ◽  
P Van Rooy ◽  
E Vercammen ◽  
...  
Keyword(s):  
Uric Acid ◽  
Potent Inhibitor ◽  
Ex Vivo ◽  
Thromboxane A2 ◽  
Chronic Administration ◽  
Response Curves ◽  
Clinically Significant ◽  
Synthase Inhibitor ◽  
The Right ◽  
Steady State Plasma Level

SummaryThe effects of ridogrel, a dual thromboxane A2 (TXA2) synthase inhibitor and TXA2/prostaglandin (PG) endoperoxide receptor antagonist, on systemic and renal production of prostaglandins and on platelet TXA2/PG endoperoxide receptors was evaluated upon chronic administration (300 mg b. i. d. orally, for 8 and 29 days) to man. Such a medication with ridogrel inhibits the systemic as well as the renal production of TXA2 as measured by the urinary excretion of 2,3-dinor-TXB2 and TXB2 respectively without inducing significant changes in systemic or renal PGI2 production. Simultaneously with the latter effects, the production of TXB2 by spontaneously coagulated whole blood ex vivo is inhibited (>99%) while that of PGE2 and PGF2α is largely increased. Administration of ridogrel causes a three- to five-fold shift to the right of concentration-response curves for U46619 in eliciting platelet aggregation; no tachyphylaxis is observed after 29 days of treatment in this respect. Apart from a reduction of serum uric acid levels with a concomitant increase in urinary uric acid excretion during the first days of treatment, no clinically significant changes in hematological, biochemical, hemodynamic and coagulation parameters occur during the 8 days or 29 days study. The study demonstrates that ridogrel is a potent inhibitor of the systemic as well as renal TXA2 synthase and an antagonist of platelet TXA2/PG endoperoxide receptor in man, covering full activity during 24 h at steady-state plasma level conditions without tachyphylaxis during 29 days of medication. The compound is well tolerated, at least during 1 month of administration.

Sign in / Sign up

Export Citation Format

Share Document